MEDI4736 (Durvalumab)
D419AC00001
Phase 3 mab active
Quick answer
MEDI4736 (Durvalumab) for Non-Small-Cell Lung Carcinoma NSCLC is a Phase 3 program (mab) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Non-Small-Cell Lung Carcinoma NSCLC
- Phase
- Phase 3
- Modality
- mab
- Status
- active